<?xml version='1.0' encoding='UTF-8'?>
<Organism_Record>
  <Organism_ID>ASD04930000_1</Organism_ID>
  <Organism>Human</Organism>
  <Organism_Latin>Homo sapiens</Organism_Latin>
  <UniProt_ID>P49841</UniProt_ID>
  <Seq_Length>420</Seq_Length>
  <Molecule_Weight>46744</Molecule_Weight>
  <KEGG_ID>hsa:2932</KEGG_ID>
  <Orthology_ID>K03083</Orthology_ID>
  <EBI_ID>EBI-373586</EBI_ID>
  <Function_Summary>Constitutively active protein kinase that acts as a negative regulator in the hormonal control of glucose homeostasis, Wnt signaling and regulation of transcription factors and microtubules, by phosphorylating and inactivating glycogen synthase (GYS1 or GYS2), EIF2B, CTNNB1/beta-catenin, APC, AXIN1, DPYSL2/CRMP2, JUN, NFATC1/NFATC, MAPT/TAU and MACF1. Requires primed phosphorylation of the majority of its substrates. In skeletal muscle, contributes to insulin regulation of glycogen synthesis by phosphorylating and inhibiting GYS1 activity and hence glycogen synthesis. May also mediate the development of insulin resistance by regulating activation of transcription factors. Regulates protein synthesis by controlling the activity of initiation factor 2B (EIF2BE/EIF2B5) in the same manner as glycogen synthase. In Wnt signaling, GSK3B forms a multimeric complex with APC, AXIN1 and CTNNB1/beta-catenin and phosphorylates the N-terminus of CTNNB1 leading to its degradation mediated by ubiquitin/proteasomes. Phosphorylates JUN at sites proximal to its DNA-binding domain, thereby reducing its affinity for DNA. Phosphorylates NFATC1/NFATC on conserved serine residues promoting NFATC1/NFATC nuclear export, shutting off NFATC1/NFATC gene regulation, and thereby opposing the action of calcineurin. Phosphorylates MAPT/TAU on 'Thr-548', decreasing significantly MAPT/TAU ability to bind and stabilize microtubules. MAPT/TAU is the principal component of neurofibrillary tangles in Alzheimer disease. Plays an important role in ERBB2-dependent stabilization of microtubules at the cell cortex. Phosphorylates MACF1, inhibiting its binding to microtubules which is critical for its role in bulge stem cell migration and skin wound repair. Probably regulates NF-kappa-B (NFKB1) at the transcriptional level and is required for the NF-kappa-B-mediated anti-apoptotic response to TNF-alpha (TNF/TNFA). Negatively regulates replication in pancreatic beta-cells, resulting in apoptosis, loss of beta-cells and diabetes. Phosphorylates MUC1 in breast cancer cells, decreasing the interaction of MUC1 with CTNNB1/beta-catenin. Is necessary for the establishment of neuronal polarity and axon outgrowth. Phosphorylates MARK2, leading to inhibit its activity. Phosphorylates SIK1 at 'Thr-182', leading to sustain its activity.</Function_Summary>
  <Catalytic_Mechanism>ATP + [tau protein] = ADP + [tau protein] phosphate.@@ATP + a protein = ADP + a phosphoprotein.</Catalytic_Mechanism>
  <Pfam_ID>PF00069:Pkinase</Pfam_ID>
  <Allosteric_Activator_Count>0</Allosteric_Activator_Count>
  <Allosteric_Inhibitor_Count>1</Allosteric_Inhibitor_Count>
  <Allosteric_Regulator_Count>0</Allosteric_Regulator_Count>
  <Alias_List>
      <Alias>Serine/threonine-protein kinase GSK3B</Alias>
      <Alias>2.7.11.1&lt;/ecNumber</Alias>
      <Alias>GSK-3 beta</Alias>
  </Alias_List>
  <Function_List>
    <Funtion>
      <Detail>Interacting selectively and non-covalently with one of the p53 family of proteins.</Detail>
      <Keyword>P53 binding</Keyword>
      <Ontology_ID>GO:0002039</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Interacting selectively and non-covalently with a ubiquitin protein ligase enzyme, any of the E3 proteins.</Detail>
      <Keyword>Ubiquitin protein ligase binding</Keyword>
      <Ontology_ID>GO:0031625</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Interacting selectively and non-covalently with a nucleotide, any compound consisting of a nucleoside that is esterified with (ortho)phosphate or an oligophosphate at any hydroxyl group on the ribose or deoxyribose.</Detail>
      <Keyword>Nucleotide binding</Keyword>
      <Ontology_ID>GO:0000166</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Interacting selectively and non-covalently with ATP, adenosine 5'-triphosphate, a universally important coenzyme and enzyme regulator.</Detail>
      <Keyword>ATP binding</Keyword>
      <Ontology_ID>GO:0005524</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Catalysis of the transfer of a group, e.g. a methyl group, glycosyl group, acyl group, phosphorus-containing, or other groups, from one compound (generally regarded as the donor) to another compound (generally regarded as the acceptor). Transferase is the systematic name for any enzyme of EC class 2.</Detail>
      <Keyword>Transferase activity</Keyword>
      <Ontology_ID>GO:0016740</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Catalysis of the reactions: ATP + protein serine = ADP + protein serine phosphate, and ATP + protein threonine = ADP + protein threonine phosphate.</Detail>
      <Keyword>Protein serine/threonine kinase activity</Keyword>
      <Ontology_ID>GO:0004674</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Catalysis of the reaction: ATP + tau-protein = ADP + O-phospho-tau-protein.</Detail>
      <Keyword>Tau-protein kinase activity</Keyword>
      <Ontology_ID>GO:0050321</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Interacting selectively and non-covalently with an RNA polymerase II transcription factor, any protein required to initiate or regulate transcription by RNA polymerase II.</Detail>
      <Keyword>RNA polymerase II transcription factor binding</Keyword>
      <Ontology_ID>GO:0001085</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Catalysis of the transfer of a phosphate group, usually from ATP, to a substrate molecule.</Detail>
      <Keyword>Kinase activity</Keyword>
      <Ontology_ID>GO:0016301</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Interacting selectively and non-covalently with one or both of the catalytic subunits of protein kinase A.</Detail>
      <Keyword>Protein kinase A catalytic subunit binding</Keyword>
      <Ontology_ID>GO:0034236</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Interacting selectively and non-covalently with the beta subunit of the catenin complex.</Detail>
      <Keyword>Beta-catenin binding</Keyword>
      <Ontology_ID>GO:0008013</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Interacting selectively and non-covalently with NF-kappaB, a transcription factor for eukaryotic RNA polymerase II promoters.</Detail>
      <Keyword>NF-kappaB binding</Keyword>
      <Ontology_ID>GO:0051059</Ontology_ID>
    </Funtion>
  </Function_List>
  <BioProcess_List>
    <BioProcess>
      <Detail>Any process that stops, prevents, or reduces the frequency, rate or extent of the chemical reactions and pathways resulting in the formation of glycogen.</Detail>
      <Keyword>Negative regulation of glycogen biosynthetic process</Keyword>
      <Ontology_ID>GO:0045719</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The series of molecular signals generated by the accumulation of normal or misfolded proteins in the endoplasmic reticulum and leading to activation of transcription by NF-kappaB.</Detail>
      <Keyword>ER overload response</Keyword>
      <Ontology_ID>GO:0006983</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that modulates the frequency, rate or extent of any cellular process that depends upon or alters the microtubule cytoskeleton.</Detail>
      <Keyword>Regulation of microtubule-based process</Keyword>
      <Ontology_ID>GO:0032886</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that activates or increases the activity of a GTPase of the Rac family.</Detail>
      <Keyword>Positive regulation of Rac GTPase activity</Keyword>
      <Ontology_ID>GO:0032855</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The series of molecular signals generated as a consequence of a fibroblast growth factor receptor binding to one of its physiological ligands.</Detail>
      <Keyword>Fibroblast growth factor receptor signaling pathway</Keyword>
      <Ontology_ID>GO:0008543</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The process in which relatively unspecialized cells, e.g. embryonic or regenerative cells, acquire specialized structural and/or functional features that characterize the cells, tissues, or organs of the mature organism or some other relatively stable phase of the organism's life history. Differentiation includes the processes involved in commitment of a cell to a specific fate and its subsequent development to the mature state.</Detail>
      <Keyword>Cell differentiation</Keyword>
      <Ontology_ID>GO:0030154</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that activates or increases the frequency, rate or extent of directed movement of proteins from the nucleus into the cytoplasm.</Detail>
      <Keyword>Positive regulation of protein export from nucleus</Keyword>
      <Ontology_ID>GO:0046827</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The process whose specific outcome is the progression of the superior temporal gyrus over time, from its formation to the mature structure. The superior temporal gyrus is a portion of the cerebral cortex that extends from the lateral sulcus to the superior temporal sulcus.</Detail>
      <Keyword>Superior temporal gyrus development</Keyword>
      <Ontology_ID>GO:0071109</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The biological process whose specific outcome is the progression of a multicellular organism over time from an initial condition (e.g. a zygote or a young adult) to a later condition (e.g. a multicellular animal or an aged adult).</Detail>
      <Keyword>Multicellular organismal development</Keyword>
      <Ontology_ID>GO:0007275</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that activates or increases the frequency, rate or extent of protein complex assembly.</Detail>
      <Keyword>Positive regulation of protein complex assembly</Keyword>
      <Ontology_ID>GO:0031334</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The phosphorylation of peptidyl-serine to form peptidyl-O-phospho-L-serine.</Detail>
      <Keyword>Peptidyl-serine phosphorylation</Keyword>
      <Ontology_ID>GO:0018105</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>A transition where an epithelial cell loses apical/basolateral polarity, severs intercellular adhesive junctions, degrades basement membrane components and becomes a migratory mesenchymal cell.</Detail>
      <Keyword>Epithelial to mesenchymal transition</Keyword>
      <Ontology_ID>GO:0001837</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The series of molecular signals initiated by binding of a Wnt protein to a frizzled family receptor on the surface of the target cell, followed by propagation of the signal via beta-catenin, and ending with a change in transcription of target genes. In this pathway, the activated receptor signals via downstream effectors that result in the inhibition of beta-catenin phosphorylation, thereby preventing degradation of beta-catenin. Stabilized beta-catenin can then accumulate and travel to the nucleus to trigger changes in transcription of target genes.</Detail>
      <Keyword>Canonical Wnt receptor signaling pathway</Keyword>
      <Ontology_ID>GO:0060070</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The series of molecular signals generated as a consequence of an epidermal growth factor receptor binding to one of its physiological ligands.</Detail>
      <Keyword>Epidermal growth factor receptor signaling pathway</Keyword>
      <Ontology_ID>GO:0007173</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The process whose specific outcome is the progression of nervous tissue over time, from its formation to its mature state.</Detail>
      <Keyword>Nervous system development</Keyword>
      <Ontology_ID>GO:0007399</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that stops, prevents, or reduces the frequency, rate or extent of cell death by apoptosis.</Detail>
      <Keyword>Negative regulation of apoptosis</Keyword>
      <Ontology_ID>GO:0043066</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that stops, prevents, or reduces the frequency, rate or extent of signal transduction.</Detail>
      <Keyword>Negative regulation of signal transduction</Keyword>
      <Ontology_ID>GO:0009968</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that stops, prevents or reduces the frequency, rate or extent of glycogen (starch) synthase activity.</Detail>
      <Keyword>Negative regulation of glycogen (starch) synthase activity</Keyword>
      <Ontology_ID>GO:2000466</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The chemical reactions and pathways involving carbohydrates, any of a group of organic compounds based of the general formula Cx(H2O)y. Includes the formation of carbohydrate derivatives by the addition of a carbohydrate residue to another molecule.</Detail>
      <Keyword>Carbohydrate metabolic process</Keyword>
      <Ontology_ID>GO:0005975</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The chemotaxis process that directs the migration of an axon growth cone to a specific target site in response to a combination of attractive and repulsive cues.</Detail>
      <Keyword>Axon guidance</Keyword>
      <Ontology_ID>GO:0007411</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that decreases the rate, frequency, or extent of the Wnt receptor signaling pathway through beta-catenin, the series of molecular signals initiated by binding of a Wnt protein to a frizzled family receptor on the surface of the target cell, followed by propagation of the signal via beta-catenin, and ending with a change in transcription of target genes.</Detail>
      <Keyword>Negative regulation of canonical Wnt receptor signaling pathway</Keyword>
      <Ontology_ID>GO:0090090</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The series of molecular signals generated as a consequence of the nerve growth factor receptor binding to one of its physiological ligands.</Detail>
      <Keyword>Nerve growth factor receptor signaling pathway</Keyword>
      <Ontology_ID>GO:0048011</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that activates or increases the frequency, rate or extent of the chemical reactions and pathways resulting in the breakdown of a protein by the destruction of the native, active configuration, with or without the hydrolysis of peptide bonds.</Detail>
      <Keyword>Positive regulation of protein catabolic process</Keyword>
      <Ontology_ID>GO:0045732</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that stops, prevents, or reduces the frequency, rate or extent of the movement of an NFAT protein from the cytoplasm to the nucleus.</Detail>
      <Keyword>Negative regulation of NFAT protein import into nucleus</Keyword>
      <Ontology_ID>GO:0051534</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that stops, prevents, or reduces the frequency, rate or extent of pancreatic B cell development.</Detail>
      <Keyword>Negative regulation of type B pancreatic cell development</Keyword>
      <Ontology_ID>GO:2000077</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The series of molecular signals initiated by binding of a Wnt protein to a frizzled family receptor on the surface of the target cell and ending with a change in cell state.</Detail>
      <Keyword>Wnt receptor signaling pathway</Keyword>
      <Ontology_ID>GO:0016055</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that stops, prevents, or reduces the frequency, rate or extent of protein complex assembly.</Detail>
      <Keyword>Negative regulation of protein complex assembly</Keyword>
      <Ontology_ID>GO:0031333</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The progression of the hippocampus over time from its initial formation until its mature state.</Detail>
      <Keyword>Hippocampus development</Keyword>
      <Ontology_ID>GO:0021766</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The chemical reactions and pathways involving glycogen, a polydisperse, highly branched glucan composed of chains of D-glucose residues in alpha(1-&gt;4) glycosidic linkage, joined together by alpha(1-&gt;6) glycosidic linkages.</Detail>
      <Keyword>Glycogen metabolic process</Keyword>
      <Ontology_ID>GO:0005977</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that activates or increases the rate or extent of cell adhesion to an extracellular matrix.</Detail>
      <Keyword>Positive regulation of cell-matrix adhesion</Keyword>
      <Ontology_ID>GO:0001954</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>A series of molecular signals in which a cell uses a phosphatidylinositol-mediated signaling to convert a signal into a response. Phosphatidylinositols include phosphatidylinositol (PtdIns) and its phosphorylated derivatives.</Detail>
      <Keyword>Phosphatidylinositol-mediated signaling</Keyword>
      <Ontology_ID>GO:0048015</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that stops, prevents, or reduces the frequency, rate or extent of protein binding.</Detail>
      <Keyword>Negative regulation of protein binding</Keyword>
      <Ontology_ID>GO:0032091</Ontology_ID>
    </BioProcess>
  </BioProcess_List>
  <PTM_List>
    <PTM>
      <Position>390</Position>
      <PTM_Type>Phosphothreonine</PTM_Type>
    </PTM>
    <PTM>
      <Position>215</Position>
      <PTM_Type>Phosphoserine</PTM_Type>
    </PTM>
    <PTM>
      <Position>415</Position>
      <PTM_Type>Phosphoserine</PTM_Type>
    </PTM>
    <PTM>
      <Position>219</Position>
      <PTM_Type>Phosphoserine</PTM_Type>
    </PTM>
    <PTM>
      <Position>389</Position>
      <PTM_Type>Phosphoserine</PTM_Type>
    </PTM>
    <PTM>
      <Position>392</Position>
      <PTM_Type>Phosphothreonine</PTM_Type>
    </PTM>
    <PTM>
      <Position>413</Position>
      <PTM_Type>Phosphoserine</PTM_Type>
    </PTM>
    <PTM>
      <Position>398</Position>
      <PTM_Type>Phosphoserine</PTM_Type>
    </PTM>
    <PTM>
      <Position>216</Position>
      <PTM_Type>Phosphotyrosine</PTM_Type>
    </PTM>
    <PTM>
      <Position>277</Position>
      <PTM_Type>Phosphothreonine</PTM_Type>
    </PTM>
    <PTM>
      <Position>25</Position>
      <PTM_Type>Phosphoserine</PTM_Type>
    </PTM>
    <PTM>
      <Position>9</Position>
      <PTM_Type>Phosphoserine</PTM_Type>
    </PTM>
    <PTM>
      <Position>275</Position>
      <PTM_Type>Phosphothreonine</PTM_Type>
    </PTM>
    <PTM>
      <Position>7</Position>
      <PTM_Type>Phosphothreonine</PTM_Type>
    </PTM>
    <PTM>
      <Position>395</Position>
      <PTM_Type>Phosphothreonine</PTM_Type>
    </PTM>
    <PTM>
      <Position>419</Position>
      <PTM_Type>Phosphoserine</PTM_Type>
    </PTM>
    <PTM>
      <Position>417</Position>
      <PTM_Type>Phosphoserine</PTM_Type>
    </PTM>
  </PTM_List>
  <Molecule_Seq>
    <Protein_Seq>MSGRPRTTSFAESCKPVQQPSAFGSMKVSRDKDGSKVTTVVATPGQGPDRPQEVSYTDTKVIGNGSFGVVYQAKLCDSGELVAIKKVLQDKRFKNRELQIMRKLDHCNIVRLRYFFYSSGEKKDEVYLNLVLDYVPETVYRVARHYSRAKQTLPVIYVKLYMYQLFRSLAYIHSFGICHRDIKPQNLLLDPDTAVLKLCDFGSAKQLVRGEPNVSYICSRYYRAPELIFGATDYTSSIDVWSAGCVLAELLLGQPIFPGDSGVDQLVEIIKVLGTPTREQIREMNPNYTEFKFPQIKAHPWTKVFRPRTPPEAIALCSRLLEYTPTARLTPLEACAHSFFDELRDPNVKLPNGRDTPALFNFTTQELSSNPPLATILIPPHARIQAAASTPTNATAASDANTGDRGQTNNAASASASNST</Protein_Seq>
    <DNA_Seq>CGGGCTTGTGCCGCCGCCGCCGCCGCCGCCGCCCGGGCCAAGTGACAAAGGAAGGAAGGAAGCGAGGAGGAGCCGGCCCCGCAGCCGCTGACAGGGCTCTGGGCTGGGGCAAAGCGCGGACACTTCCTGAGCGGGCACCGAGCAGAGCCGAGGGGCGGGAGGGCGGCCGAGCTGTTGCCGCGGACGGGGGAGGGGGCCCCGAGGGACGGAAGCGGTTGCCGGGTTCCCATGTCCCCGGCGAATGGGGAACAGTCGAGGAGCCGCTGCCTGGGGTCTGAAGGGAGCTGCCTCCGCCACCGCCATGGCCGCTGGATCCAGCCGCCGCCTGCAGCTGCTCCTGGCGCAATGAGGAGAGGAGCCGCCGCCACCGCCACCGCCCGCCTCTGACTGACTCGCGACTCCGCCGCCCTCTAGTTCGCCGGGCCCCTGCCGTCAGCCCGCCGGATCCCGCGGCTTGCCGGAGCTGCAGCGTTTCCCGTCGCATCTCCGAGCCACCCCCTCCCTCCCTCTCCCTCCCTCCTACCCATCCCCCTTTCTCTTCAAGCGTGAGACTCGTGATCCTTCCGCCGCTTCCCTTCTTCATTGACTCGGAAAAAAAATCCCCGAGGAAAATATAATATTCGAAGTACTCATTTTCAATCAAGTATTTGCCCCCGTTTCACGTGATACATATTTTTTTAGGATTTGCCCTCTCTTTTCTCTCCTCCCAGGAAAGGGAGGGGAAAGAATTGTATTTTTTCCCAAGTCCTAAATCATCTATATGTTAAATATCCGTGCCGATCTGTCTTGAAGGAGAAATATATCGCTTGTTTTGTTTTTTATAGTATACAAAAGGAGTGAAAAGCCAAGAGGACGAAGTCTTTTTCTTTTTCTTCTGTGGGAGAACTTAATGCTGCATTTATCGTTAACCTAACACCCCAACATAAAGACAAAAGGAAGAAAAGGAGGAAGGAAGGAAAAGGTGATTCGCGAAGAGAGTGATCATGTCAGGGCGGCCCAGAACCACCTCCTTTGCGGAGAGCTGCAAGCCGGTGCAGCAGCCTTCAGCTTTTGGCAGCATGAAAGTTAGCAGAGACAAGGACGGCAGCAAGGTGACAACAGTGGTGGCAACTCCTGGGCAGGGTCCAGACAGGCCACAAGAAGTCAGCTATACAGACACTAAAGTGATTGGAAATGGATCATTTGGTGTGGTATATCAAGCCAAACTTTGTGATTCAGGAGAACTGGTCGCCATCAAGAAAGTATTGCAGGACAAGAGATTTAAGAATCGAGAGCTCCAGATCATGAGAAAGCTAGATCACTGTAACATAGTCCGATTGCGTTATTTCTTCTACTCCAGTGGTGAGAAGAAAGATGAGGTCTATCTTAATCTGGTGCTGGACTATGTTCCGGAAACAGTATACAGAGTTGCCAGACACTATAGTCGAGCCAAACAGACGCTCCCTGTGATTTATGTCAAGTTGTATATGTATCAGCTGTTCCGAAGTTTAGCCTATATCCATTCCTTTGGAATCTGCCATCGGGATATTAAACCGCAGAACCTCTTGTTGGATCCTGATACTGCTGTATTAAAACTCTGTGACTTTGGAAGTGCAAAGCAGCTGGTCCGAGGAGAACCCAATGTTTCGTATATCTGTTCTCGGTACTATAGGGCACCAGAGTTGATCTTTGGAGCCACTGATTATACCTCTAGTATAGATGTATGGTCTGCTGGCTGTGTGTTGGCTGAGCTGTTACTAGGACAACCAATATTTCCAGGGGATAGTGGTGTGGATCAGTTGGTAGAAATAATCAAGGTCCTGGGAACTCCAACAAGGGAGCAAATCAGAGAAATGAACCCAAACTACACAGAATTTAAATTCCCTCAAATTAAGGCACATCCTTGGACTAAGGTCTTCCGACCCCGAACTCCACCGGAGGCAATTGCACTGTGTAGCCGTCTGCTGGAGTATACACCAACTGCCCGACTAACACCACTGGAAGCTTGTGCACATTCATTTTTTGATGAATTACGGGACCCAAATGTCAAACTACCAAATGGGCGAGACACACCTGCACTCTTCAACTTCACCACTCAAGAACTGTCAAGTAATCCACCTCTGGCTACCATCCTTATTCCTCCTCATGCTCGGATTCAAGCAGCTGCTTCAACCCCCACAAATGCCACAGCAGCGTCAGATGCTAATACTGGAGACCGTGGACAGACCAATAATGCTGCTTCTGCATCAGCTTCCAACTCCACCTGAACAGTCCCGAGCAGCCAGCTGCACAGGAAAAACCACCAGTTACTTGAGTGTCACTCAGCAACACTGGTCACGTTTGGAAAGAATATTAAAAAGAGAAAAAAATCCTGTTCATTTTAGTGTTCAATTTTTTTATTATTATTGTTGTTCTTATTTAACCTTGTAAAATATCTATAAATACAAACCAATTTCATTGTATTCTCACTTTGAGGGAGATCCAGGGGGTGGGAGGGGTTGTGGGGAGGGGGAAAGCGGAGCACTAGAACATACAATCTCTCTCCCACGACAATCTTTTTTTATTAAAAGTCTGCTGTTGTATACTTTAAAAACAGGACTCCTGCCTCATGCCCCTTCCACAAAAGAAGAAAACCTTTTTCTGTGCTGATGGGTTTTTTTGAACTTTGTTTTCTTTTAAAGTCTAGTGTGAGACTTTGGTATAGTGCACAGCTTGAAATTGGTTGGGAGCTTAGCAGGTATAACTCAACGGGGACTTAAATGTCACTTGTAAAATTAATCCATATCTTCGGGTATTTATAGACTTGCCTTTGGCATGTTGGTGGCAGGTGTGGCAGACAAAGAAATGTGTATCATTCGTAACCCAGGGAGGTCAATAAAGTTTGGAACTCTACAGGGAAGATTCTTAGTAGATTTGTTAAGGTTTTGTTTTGCTCTCAGTTAGTGCTAGTGATGTAGAGGCTTGTACAGGAGGCTGCCAGAGGGGAAGCAGCAAGCAAGACTCAGGCACACATGCTCTACAGGTGGCTCTTTGTTTGCCTGACCAAAGTTCTTTGCAAATCTTAGCACAGTTTCAAACTAGTGACCTGGGAGGAGATGGAAGGGGTGTTGAGCAGGCTGAGCTAGCTGCTGAGGTCAAAGGCTGATGAGCCCAGAGGAAGGGGACAGGTCAGGGATACATCTCACCACTGTGAATAAGTTTGTCCAGATTTTTTTCTAAAGTTACTTCCCTTGGAAAGATACACTTGAGAGGACATTGTAGTTAAATAATGTGAACTGTAACAGTCATCTACTGGTTTATTTTTCATATTTTTTAATTGAAAATTGAGCTTGCAGAAATAGCCACATTCTACACATAGTTCTAATTTTAAATCCAAATCTAGAATCTGTATTTAATTTGTTTTTTAACCTCATGCTTTTTACATTTATTTATTGATGCATGTCAGATGGTAGAAATATTAAAAACTACACATCAGAATGATACAGTCACTTATACCTGCTGACTTTATAGGAAAGCTGATGATATAAATGTGTGTATATATGTTATATATACATATATTCAATACTGCCTTTTTTTTTGTCTACAGTATCAAAATTGACTGGTTGAAGCATGAGAAGAATGTTTCCCCCACACCCAGTTAAGAGTTTTTGTGTCTGTTTTCTTTGTGTATCAGTGAACGATGTTAAGAATCAGTCTCTCTTTTTGAAGAAAAAGCAATATTCCTTGGAAAGCAAGGAGAATTGAAGGACTATGTTTGCCGTGAGGAAATAGATTTTCATGACTAGTTTGTTTTATACTTTTAAGGTTGGCATCTATGTGGGCCTTATATACTCTAAAATGAACTTTAGTCACCTTGGTGCTTATGGGCCATTACTTGACCTATGAATCTTTAAGGCACAATCAGTTGTACTTTACATTTAAAGATCACTTGAGTGATGGCCGCCTTTCCCTCCTACCCGCTCCTTCCCCACATGCCTTCCAAGGTTAGCTGGTAACTGTAGGGCTGCAGAGCTGAGCCCATGGTTGTGTGTAACTTGCCCTCACCCTCCTCATTGCCACCTTAGGTCACTTTATGGGTCTCGTCCTCCAGAGGGTTCGGAAGTGGAGTCTGTTGGCAGCCCTCCTGCAGGCCCTAGCACCCTGTCCTGCTCCTTAACTGTGTGTGTGACTCTCCAAGAGAGTTGTCCTGCCTGCTGAAGTGAACCAGTACCCAGAAAGACAACTGTGAGCCATCTTGGTTTTCACTCGCTGTTTAGCTGAGGTCTTGGGCCACAAAAGGGGTTTCACAAACCTCTGGATATATCAGAGTTTATGAGAAAGGAAACATGCTCAGTCAAACCAAATCAAACAAATTGAATTTTATGTTTTATAAAGTGCTTCTGAAAGCTAAGATTTGAAAGAAGTCTGAAATCAAAGTATTTGGCAGCATAACTCCTTAAAGGTAGTGGCGTTGATAGACCATTTTCAGACAGAATTTATAAAGAATCTGAAAAGGCAGGTCTGTGATAGAGAAATGGACCTGCATTCAGATCCAACTGCCCAGCAAGCGTTTGGATGCAGACACTGCTCTGGACGTGGTATACTCCCCAGAGTCCATAAAAATCAGTGCTTATTTTAGGAAACAGGTTGCCCCCCACAACTGGGGTAAAAGAAGAGAGAAAAGTCACGCTTTTCTCTCATTTCATTGTGTGTGCATGTGTGCGTGTGTGTGTGTGTGTGTGTGTGCTGAGATGTGTGATTTTTCTTTCTCAAGGATCATGGTGGGATCACAGAACTCTTTTATACAAGTGAGATCCAGGTCTCTGAATATCTTTTTGTATATAATAATAATAAAAAGCTCCTCACCAAATTCAAGCTTGTACATTATATTTTCTTTCTGTGTTTTTAAATTTAAGTTTTATTGTTTTGTATGTAAATATGTGGACCCAGGAACTGTTATTAATGAGCAAAAAGTTACTGTTCAGGGCAGTGATTCTGTTTAATAATCAGACAAAATGTAGACGAGCTTTTTAAAGCCATATAGTTTTAACTCTGTACAGTAGGTACCGGCCTGTATTATTGTAACAATAACTCTAGCAATGTATAGTGTATCTATATAGTTTGGAGTGCCTTCGCTTCCATGTGTTTTTTTTTTTAATTTGTTCTTTTTTAAATTTTAATTGGTTTCCTTTATCCATGTCTCCCTGTCCACCCCCTTTCCCTTTGAAATAATAACTCACTCATAACAGTATCTTTGCCCCTTCCACAGTTAAGTTTCAGTGATACCATACTCAGGAGTGGGAAGAGGAAATCATATTCGTAATTTCATTTCGTTGAAGCCCTGCCTTTGTTTTGGTTCTGAATGTCTTTCCTCCTCGGTAGCAGTGAGACCGGTTTCATTTCATACTTAGTCCATTCAGGGACTTAGTGTAGCACCAGGGAGCCCTAGAGCTGGAGGATATCGAATAGATTAAATTTTGCTCGTCTCTTCCACAAGCCCTAACCATGGGTCTTAAAAACAGCAGATTCTGGGAGCCTTCCATGCTCTCTCTCTCTCCTCTTTTATCTACTTCCCTCCCAAATGAGAGAGTGACAGAGAATTGTTTTTTTATAAATCGAAGTTTCTTAATAGTATCAGGTTTTGATACGTCAGTGGTCTAAAATGCTATAGTGCAATTACTAGCAGTTACTGCACGGAGTGCCACCGTGCCAATAGAGGACTGTTGTTTTAACAAGGGAACTCTTAGCCCATTTCCTCCCTCCCGCCATCTCTACCCTTGCTCAATGAAATATCATTTTAATTTCTTTTAAAAAAAATCAGTTTAATTCTTACTGTGTGCCCAACACGAAGGCCTTTTTTGAAAGAAAAATAGAATGTTTTGCCTCAAAGTAGTCCATATAAAATGTCTTGAATAGAAGAAAAAACTACCAAACCAAAGGTTACTATTTTTGAAACATCGTGTGTTCATTCCAGCAAGGCAGAAGACTGCACCTTCTTTCCAGTGACATGCTGTGTCATTTTTTTTAAGTCCTCTTAATTTTTAGACACATTTTTGGTTTATGTTTTAACAATGTATGCCTAACCAGTCATCTTGTCTGCACCAATGCAAAGGTTTCTGAGAGGAGTATTCTCTATCCCTGTGGATATGAAGACACTGGCATTTCATCTATTTTTCCCTTTCCTTTTTAAAGGATTTAACTTTGGAATCTTCCAAAGGAAGTTTGGCCAATGCCAGATCCCCAGGAATTTGGGGGGTTTTCTTTCTTTTCAACTGAAATTGTATCTGATTCCTACTGTTCATGTTAGTGATCATCTAATCACAGAGCCAAACACTTTTCTCCCCTGTGTGGAAAAGTAGGTATGCTTTACAATAAAATCTGTCTTTTCTGGTAGAAACCTGAGCCACTGAAAATAAAAGAGACAACTAGAAGCACAGTAGAGTCCCAGACTGAGATCTACCTTTGAGAGGCTTTGAAAGTAATCCCTGGGGTTTGGATTATTTTCACAAGGGTTATGCCGTTTTATTCAAGTTTGTTGCTCCGTTTTGCACCTCTGCAATAAAAGCAAAATGACAACCAGTACATAAGGGGTTAGCTTGACAAAGTAGACTTCCTTGTGTTAATTTTTAAGTTTTTTTTTCCTTAACTATATCTGTCTACAGGCAGATACAGATAGTTGTATGAAAATCTGCTTGCCTGTAAAATTTGCATTTATAAATGTGTTGCCGATGGATCACTTGGGCCTGTACACATACCAATTAGCGTGACCACTTCCATCTTAAAAACAAACCTAAAAAACAAAATTTATTATATATATATATATATATATATAAAGGACTGTGGGTTGTATACAAACTATTGCAAACACTTGTGCAAATCTGTCTTGATATAAAGGAAAAGCAAAATCTGTATAACATTATTACTACTTGAATGCCTCTGTGACTGATTTTTTTTTCATTTTAAATATAAACTTTTTTGTGAAAAGTATGCTCAATGTTTTTTTTCCCTTTCCCCATTCCCTTGTAAATACATTTTGTTCTATGTGACTTGGTTTGGAAATAGTTAACTGGTACTGTAATTTGCATTAAATAAAAAGTAGGTTAGCCTGGAAATGAAATTAAAAAAAAAAAAAAAAAA</DNA_Seq>
  </Molecule_Seq>
  <Tissuelocal_List>
    <TissueLocal>
      <TissueLocal>Ovary</TissueLocal>
    </TissueLocal>
    <TissueLocal>
      <TissueLocal>Testis</TissueLocal>
    </TissueLocal>
    <TissueLocal>
      <TissueLocal>Brain</TissueLocal>
    </TissueLocal>
    <TissueLocal>
      <TissueLocal>Kidney</TissueLocal>
    </TissueLocal>
    <TissueLocal>
      <TissueLocal>Prostate</TissueLocal>
    </TissueLocal>
    <TissueLocal>
      <TissueLocal>Thymus</TissueLocal>
    </TissueLocal>
    <TissueLocal>
      <TissueLocal>Lung</TissueLocal>
    </TissueLocal>
  </Tissuelocal_List>
  <CellLocal_List>
    <AsdMacromoleculeCelllocal>
        <CellLocal>Axin-APC-beta-catenin-GSK3B complex</CellLocal>
      <Ontology_ID>GO:0034747</Ontology_ID>
    </AsdMacromoleculeCelllocal>
    <AsdMacromoleculeCelllocal>
        <CellLocal>Nucleus</CellLocal>
      <Ontology_ID>GO:0005634</Ontology_ID>
    </AsdMacromoleculeCelllocal>
    <AsdMacromoleculeCelllocal>
        <CellLocal>Plasma membrane</CellLocal>
      <Ontology_ID>GO:0005886</Ontology_ID>
    </AsdMacromoleculeCelllocal>
    <AsdMacromoleculeCelllocal>
        <CellLocal>Membrane</CellLocal>
      <Ontology_ID>GO:0016020</Ontology_ID>
    </AsdMacromoleculeCelllocal>
    <AsdMacromoleculeCelllocal>
        <CellLocal>Cytosol</CellLocal>
      <Ontology_ID>GO:0005829</Ontology_ID>
    </AsdMacromoleculeCelllocal>
    <AsdMacromoleculeCelllocal>
        <CellLocal>Cell membrane</CellLocal>
      <Ontology_ID>SwissProt</Ontology_ID>
    </AsdMacromoleculeCelllocal>
    <AsdMacromoleculeCelllocal>
        <CellLocal>Cytoplasm</CellLocal>
      <Ontology_ID>GO:0005737</Ontology_ID>
    </AsdMacromoleculeCelllocal>
    <AsdMacromoleculeCelllocal>
        <CellLocal>Beta-catenin destruction complex</CellLocal>
      <Ontology_ID>GO:0030877</Ontology_ID>
    </AsdMacromoleculeCelllocal>
    <AsdMacromoleculeCelllocal>
        <CellLocal>Centrosome</CellLocal>
      <Ontology_ID>GO:0005813</Ontology_ID>
    </AsdMacromoleculeCelllocal>
  </CellLocal_List>
  <Gene>
    <Gene_Name>GSK3B</Gene_Name>
    <Gene_ID>2932</Gene_ID>
    <Genbank_ACCN>NM_001146156</Genbank_ACCN>
    <Protein_ACCN>NP_001139628</Protein_ACCN>
    <HGNC_ID>4617</HGNC_ID>
    <Gene_URL>http://www.ncbi.nlm.nih.gov/gene/2932</Gene_URL>
    <UCSC_ID>uc003edo.3</UCSC_ID>
    <EMBL_ID>ENSG00000082701</EMBL_ID>
  </Gene>
  <PPI_List>
    <PPI>
      <Uniprot_ID>Q811T9</Uniprot_ID>
      <Gene_Name>Disc1</Gene_Name>
      <EBI_ID>EBI-2298259</EBI_ID>
      <PPI_EBI_URL>EBI-373586,EBI-2298259</PPI_EBI_URL>
      <Experiment_Number>4</Experiment_Number>
    </PPI>
    <PPI>
      <Uniprot_ID>P35222</Uniprot_ID>
      <Gene_Name>CTNNB1</Gene_Name>
      <EBI_ID>EBI-491549</EBI_ID>
      <PPI_EBI_URL>EBI-373586,EBI-491549</PPI_EBI_URL>
      <Experiment_Number>3</Experiment_Number>
    </PPI>
    <PPI>
      <Uniprot_ID>Q14134</Uniprot_ID>
      <Gene_Name>TRIM29</Gene_Name>
      <EBI_ID>EBI-702370</EBI_ID>
      <PPI_EBI_URL>EBI-373586,EBI-702370</PPI_EBI_URL>
      <Experiment_Number>2</Experiment_Number>
    </PPI>
    <PPI>
      <Uniprot_ID>Q01201</Uniprot_ID>
      <Gene_Name>RELB</Gene_Name>
      <EBI_ID>EBI-357837</EBI_ID>
      <PPI_EBI_URL>EBI-373586,EBI-357837</PPI_EBI_URL>
      <Experiment_Number>4</Experiment_Number>
    </PPI>
    <PPI>
      <Uniprot_ID>O15169</Uniprot_ID>
      <Gene_Name>AXIN1</Gene_Name>
      <EBI_ID>EBI-710484</EBI_ID>
      <PPI_EBI_URL>EBI-373586,EBI-710484</PPI_EBI_URL>
      <Experiment_Number>9</Experiment_Number>
    </PPI>
    <PPI>
      <Uniprot_ID>P31751</Uniprot_ID>
      <Gene_Name>AKT2</Gene_Name>
      <EBI_ID>EBI-296058</EBI_ID>
      <PPI_EBI_URL>EBI-373586,EBI-296058</PPI_EBI_URL>
      <Experiment_Number>2</Experiment_Number>
    </PPI>
    <PPI>
      <Uniprot_ID>Q14DJ8</Uniprot_ID>
      <Gene_Name>Axin1</Gene_Name>
      <EBI_ID>EBI-4312125</EBI_ID>
      <PPI_EBI_URL>EBI-373586,EBI-4312125</PPI_EBI_URL>
      <Experiment_Number>2</Experiment_Number>
    </PPI>
    <PPI>
      <Uniprot_ID>P63085</Uniprot_ID>
      <Gene_Name>Mapk1</Gene_Name>
      <EBI_ID>EBI-397697</EBI_ID>
      <PPI_EBI_URL>EBI-373586,EBI-397697</PPI_EBI_URL>
      <Experiment_Number>2</Experiment_Number>
    </PPI>
    <PPI>
      <Uniprot_ID>P31749</Uniprot_ID>
      <Gene_Name>AKT1</Gene_Name>
      <EBI_ID>EBI-296087</EBI_ID>
      <PPI_EBI_URL>EBI-373586,EBI-296087</PPI_EBI_URL>
      <Experiment_Number>2</Experiment_Number>
    </PPI>
    <PPI>
      <Uniprot_ID>Q8IX07</Uniprot_ID>
      <Gene_Name>ZFPM1</Gene_Name>
      <EBI_ID>EBI-3942619</EBI_ID>
      <PPI_EBI_URL>EBI-373586,EBI-3942619</PPI_EBI_URL>
      <Experiment_Number>2</Experiment_Number>
    </PPI>
    <PPI>
      <Uniprot_ID>Q8N4C6</Uniprot_ID>
      <Gene_Name>NIN</Gene_Name>
      <EBI_ID>EBI-1164022</EBI_ID>
      <PPI_EBI_URL>EBI-373586,EBI-1164022</PPI_EBI_URL>
      <Experiment_Number>2</Experiment_Number>
    </PPI>
    <PPI>
      <Uniprot_ID>O75398</Uniprot_ID>
      <Gene_Name>DEAF1</Gene_Name>
      <EBI_ID>EBI-718185</EBI_ID>
      <PPI_EBI_URL>EBI-373586,EBI-718185</PPI_EBI_URL>
      <Experiment_Number>2</Experiment_Number>
    </PPI>
    <PPI>
      <Uniprot_ID>O95863</Uniprot_ID>
      <Gene_Name>SNAI1</Gene_Name>
      <EBI_ID>EBI-1045459</EBI_ID>
      <PPI_EBI_URL>EBI-373586,EBI-1045459</PPI_EBI_URL>
      <Experiment_Number>4</Experiment_Number>
    </PPI>
  </PPI_List>
  <Disease_List>
    <Disease>
      <Disease_Name>Waardenburg Syndrome Type 2</Disease_Name>
      <Disease_Detail>Waardenburg Syndrome Type 2</Disease_Detail>
      <Disease_DB>WRD006</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/waardenburg_syndrome_type_2?search=GSK3B#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Aneurysmal Bone Cysts</Disease_Name>
      <Disease_Detail>Aneurysmal Bone Cysts</Disease_Detail>
      <Disease_DB>ANR009</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/aneurysmal_bone_cysts?search=GSK3B#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Leopard Syndrome</Disease_Name>
      <Disease_Detail>Leopard Syndrome</Disease_Detail>
      <Disease_DB>LPR002</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/leopard_syndrome?search=GSK3B#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Alzheimer's Disease</Disease_Name>
      <Disease_Detail>Alzheimer's Disease</Disease_Detail>
      <Disease_DB>ALZ001</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/alzheimers_disease?search=GSK3B#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Parkinson's Disease</Disease_Name>
      <Disease_Detail>Parkinson's Disease</Disease_Detail>
      <Disease_DB>PRK002</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/parkinsons_disease?search=GSK3B#related_genes</Disease_URL>
    </Disease>
  </Disease_List>
  <PDB_List>
    <PDB>
      <PDB_Title>GSK-3 Beta complexed with Alsterpaullone</PDB_Title>
      <PDB_ID>1Q3W</PDB_ID>
      <Resolution>2.3</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1Q3W</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Structural Characterization of the Gsk-3Beta Active Site Using Selective and Non-selective ATP-Mimetic Inhibitors</PubMed_Title>
      <Author>Bertrand JA, et al.</Author>
      <Journal>J Mol Biol. 2003,333(2):393-407.</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/14529625?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Structure of Ruthenium Half-Sandwich Complex Bound to Glycogen Synthase Kinase 3</PDB_Title>
      <PDB_ID>3M1S</PDB_ID>
      <Resolution>3.13</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3M1S</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Structure of anticancer ruthenium half-sandwich complex bound to glycogen synthase kinase 3beta.</PubMed_Title>
      <Author>Atilla-Gokcumen GE, et al.</Author>
      <Journal>J Biol Inorg Chem. 2011 Jan;16(1):45-50.</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/20821241?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>STRUCTURE OF 4-(4-TERT-BUTYLBENZYL)-1-(7H-PYRROLO(2,3-D) PYRIMIDIN-4-YL)PIPERIDIN-4-AMINE BOUND TO PKB</PDB_Title>
      <PDB_ID>2XH5</PDB_ID>
      <Resolution>2.72</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2XH5</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Discovery of 4-Amino-1-(7H-Pyrrolo[2,3-D]Pyrimidin-4-Yl)Piperidine-4-Carboxamides as Selective, Orally Active Inhibitors of Protein Kinase B (Akt).</PubMed_Title>
      <Author>McHardy T, et al.</Author>
      <Journal>J Med Chem. 2010 Mar 11;53(5):2239-49.</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/20151677?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Binary complex structure of human tau protein kinase I with ADP</PDB_Title>
      <PDB_ID>1J1C</PDB_ID>
      <Resolution>2.1</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1J1C</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Structural insight into nucleotide recognition in tau-protein kinase I/glycogen synthase kinase 3 beta.</PubMed_Title>
      <Author>Aoki M, et al.</Author>
      <Journal>Acta Crystallogr D Biol Crystallogr. 2004 Mar;60(Pt 3):439-46.</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/14993667?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>GLYCOGEN SYNTHASE KINASE 3 BETA COMPLEXED WITH AXIN PEPTIDE</PDB_Title>
      <PDB_ID>1O9U</PDB_ID>
      <Resolution>2.4</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1O9U</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Structural Basis for Recruitment of Glycogen Synthase Kinase 3Beta to the Axin-Apc Scaffold Complex</PubMed_Title>
      <Author>Dajani R, et al.</Author>
      <Journal>EMBO J. 2003 Feb 3;22(3):494-501.</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/12554650?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structure of GSK-3 beta in complex with NMS-869553A</PDB_Title>
      <PDB_ID>3DU8</PDB_ID>
      <Resolution>2.2</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3DU8</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>First Cdc7 kinase inhibitors: pyrrolopyridinones as potent and orally active antitumor agents. 2. Lead discovery.</PubMed_Title>
      <Author>Menichincheri M, et al.</Author>
      <Journal>J Med Chem. 2009 Jan 22;52(2):293-307.</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/19115845?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>EXTREMELY TIGHT BINDING OF RUTHENIUM COMPLEX TO GLYCOGEN SYNTHASE KINASE 3</PDB_Title>
      <PDB_ID>2JLD</PDB_ID>
      <Resolution>2.35</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2JLD</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Extremely Tight Binding of a Ruthenium Complex to Glycogen Synthase Kinase 3.</PubMed_Title>
      <Author>Atilla-Gokcumen GE, et al.</Author>
      <Journal>Chembiochem. 2008 Dec 15;9(18):2933-6.</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/19035373?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal Structure of GSK3beta in complex with a benzoimidazol inhibitor</PDB_Title>
      <PDB_ID>2O5K</PDB_ID>
      <Resolution>3.2</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2O5K</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Design and synthesis of 7-hydroxy-1H-benzoimidazole derivatives as novel inhibitors of glycogen synthase kinase-3beta</PubMed_Title>
      <Author>Shin D, et al.</Author>
      <Journal>Bioorg Med Chem Lett. 2007 Oct 15;17(20):5686-9.</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/17764934?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>STRUCTURE OF PKB-BETA (AKT2) COMPLEXED WITH 4-(4-CHLORO-PHENYL)-4-(4-(1H-PYRAZOL-4-YL)-PHENYL)-PIPERIDINE</PDB_Title>
      <PDB_ID>2UW9</PDB_ID>
      <Resolution>2.1</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2UW9</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Identification of Inhibitors of Protein Kinase B Using Fragment-Based Lead Discovery.</PubMed_Title>
      <Author>Saxty G, et al.</Author>
      <Journal>J Med Chem. 2007 May 17;50(10):2293-6.</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/17451234?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>STRUCTURE OF PKB-BETA (AKT2) COMPLEXED WITH ISOQUINOLINE-5-SULFONIC ACID (2-(2-(4-CHLOROBENZYLOXY) ETHYLAMINO)ETHYL) AMIDE</PDB_Title>
      <PDB_ID>2JDO</PDB_ID>
      <Resolution>1.8</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2JDO</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>A Structural Comparison of Inhibitor Binding to Pkb, Pka and Pka-Pkb Chimera</PubMed_Title>
      <Author>Davies TG, et al.</Author>
      <Journal>J Mol Biol. 2007 Mar 30;367(3):882-94.</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/17275837?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>X-ray Co-Crystal Structure of Glycogen Synthase Kinase 3beta in Complex with an Inhibitor</PDB_Title>
      <PDB_ID>3F7Z</PDB_ID>
      <Resolution>2.4</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3F7Z</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Design, synthesis and structure-activity relationships of 1,3,4-oxadiazole derivatives as novel inhibitors of glycogen synthase kinase-3beta.</PubMed_Title>
      <Author>Saitoh M, et al.</Author>
      <Journal>Bioorg Med Chem. 2009 Mar 1;17(5):2017-29.</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/19200745?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structures of the kinase domain of AKT2 in complex with ATP-competitive inhibitors</PDB_Title>
      <PDB_ID>3E88</PDB_ID>
      <Resolution>2.5</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3E88</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Aminofurazans as potent inhibitors of AKT kinase</PubMed_Title>
      <Author>Rouse MB, et al.</Author>
      <Journal>Bioorg Med Chem Lett. 2009 Mar 1;19(5):1508-11.</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/19179070?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>GSK3beta inhibitor complex</PDB_Title>
      <PDB_ID>3GB2</PDB_ID>
      <Resolution>2.4</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3GB2</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>2-{3-[4-(Alkylsulfinyl)phenyl]-1-benzofuran-5-yl}-5-methyl-1,3,4-oxadiazole derivatives as novel inhibitors of glycogen synthase kinase-3beta with good brain permeability.</PubMed_Title>
      <Author>Saitoh M, et al.</Author>
      <Journal>J Med Chem. 2009 Oct 22;52(20):6270-86.</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/19775160?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structures of the kinase domain of AKT2 in complex with ATP-competitive inhibitors</PDB_Title>
      <PDB_ID>3E87</PDB_ID>
      <Resolution>2.3</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3E87</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Aminofurazans as potent inhibitors of AKT kinase</PubMed_Title>
      <Author>Rouse MB, et al.</Author>
      <Journal>Bioorg Med Chem Lett. 2009 Mar 1;19(5):1508-11.</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/19179070?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>GSK-3 Beta complexed with Inhibitor I-5</PDB_Title>
      <PDB_ID>1Q4L</PDB_ID>
      <Resolution>2.77</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1Q4L</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Structural Characterization of the Gsk-3Beta Active Site Using Selective and Non-selective ATP-Mimetic Inhibitors</PubMed_Title>
      <Author>Bertrand JA, et al.</Author>
      <Journal>J Mol Biol. 2003,333(2):393-407.</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/14529625?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>STRUCTURE OF 4-AMINO-N-(4-CHLOROBENZYL)-1-(7H-PYRROLO(2,3-D) PYRIMIDIN-4-YL)PIPERIDINE-4-CARBOXAMIDE BOUND TO PKB</PDB_Title>
      <PDB_ID>2X39</PDB_ID>
      <Resolution>1.93</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2X39</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Discovery of 4-Amino-1-(7H-Pyrrolo[2,3-D]Pyrimidin-4-Yl)Piperidine-4-Carboxamides as Selective, Orally Active Inhibitors of Protein Kinase B (Akt).</PubMed_Title>
      <Author>McHardy T, et al.</Author>
      <Journal>J Med Chem. 2010 Mar 11;53(5):2239-49.</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/20151677?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structure of GSK3b in complex with a pyrimidylpyrrole inhibitor</PDB_Title>
      <PDB_ID>3I4B</PDB_ID>
      <Resolution>2.3</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3I4B</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Structure-guided design of potent and selective pyrimidylpyrrole inhibitors of extracellular signal-regulated kinase (ERK) using conformational control.</PubMed_Title>
      <Author>Aronov AM, et al.</Author>
      <Journal>J Med Chem. 2009 Oct 22;52(20):6362-8.</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/19827834?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>crystal structure of Glycogen synthase kinase 3 in complexed with inhibitor</PDB_Title>
      <PDB_ID>1Q5K</PDB_ID>
      <Resolution>1.94</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1Q5K</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Structural insights and biological effects of glycogen synthase kinase 3-specific inhibitor AR-A014418.</PubMed_Title>
      <Author>Bhat R, et al.</Author>
      <Journal>J Biol Chem. 2003 Nov 14;278(46):45937-45.</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/12928438?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>STRUCTURE OF GLYCOGEN SYNTHASE KINASE-3 (GSK3B)</PDB_Title>
      <PDB_ID>1I09</PDB_ID>
      <Resolution>2.7</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1I09</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Structure of GSK3beta reveals a primed phosphorylation mechanism.</PubMed_Title>
      <Author>ter Haar E, et al.</Author>
      <Journal>Nat Struct Biol. 2001 Jul;8(7):593-6.</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/11427888?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Structure of Glycogen Synthase Kinase 3 beta (GSK3B) in complex with a ruthenium octasporine ligand (OS1)</PDB_Title>
      <PDB_ID>3PUP</PDB_ID>
      <Resolution>2.99</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3PUP</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Structurally Sophisticated Octahedral Metal Complexes as Highly Selective Protein Kinase Inhibitors.</PubMed_Title>
      <Author>Feng L, et al.</Author>
      <Journal>J Am Chem Soc. 2011 Apr 20;133(15):5976-5986.</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/21446733?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>STRUCTURE OF PKB-BETA (AKT2) COMPLEXED WITH THE INHIBITOR A-443654</PDB_Title>
      <PDB_ID>2JDR</PDB_ID>
      <Resolution>2.3</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2JDR</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>A Structural Comparison of Inhibitor Binding to Pkb, Pka and Pka-Pkb Chimera</PubMed_Title>
      <Author>Davies TG, et al.</Author>
      <Journal>J Mol Biol. 2007 Mar 30;367(3):882-94.</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/17275837?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Binary complex structure of human tau protein kinase I with AMPPNP</PDB_Title>
      <PDB_ID>1J1B</PDB_ID>
      <Resolution>1.8</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1J1B</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Structural insight into nucleotide recognition in tau-protein kinase I/glycogen synthase kinase 3 beta.</PubMed_Title>
      <Author>Aoki M, et al.</Author>
      <Journal>Acta Crystallogr D Biol Crystallogr. 2004 Mar;60(Pt 3):439-46.</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/14993667?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Glycogen synthase kinase-3 beta in complex with bis-(indole)maleimide pyridinophane inhibitor</PDB_Title>
      <PDB_ID>2OW3</PDB_ID>
      <Resolution>2.8</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2OW3</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Novel bis(indolyl)maleimide pyridinophanes that are potent, selective inhibitors of glycogen synthase kinase-3.</PubMed_Title>
      <Author>Zhang HC, et al.</Author>
      <Journal>Bioorg Med Chem Lett. 2007 May 15;17(10):2863-8.</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/17350261?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>GSK-3 Beta complexed with Staurosporine</PDB_Title>
      <PDB_ID>1Q3D</PDB_ID>
      <Resolution>2.2</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1Q3D</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Structural Characterization of the Gsk-3Beta Active Site Using Selective and Non-selective ATP-Mimetic Inhibitors</PubMed_Title>
      <Author>Bertrand JA, et al.</Author>
      <Journal>J Mol Biol. 2003,333(2):393-407.</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/14529625?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>GLYCOGEN SYNTHASE KINASE 3 BETA</PDB_Title>
      <PDB_ID>1H8F</PDB_ID>
      <Resolution>2.8</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1H8F</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Crystal Structure of Glycogen Synthase Kinase 3Beta . Structural Basis for Phosphate-Primed Substrate Specificity and Autoinhibition</PubMed_Title>
      <Author>Dajani R, et al.</Author>
      <Journal>Cell. 2001,105(6):721-732.</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/11440715?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>GLYCOGEN SYNTHASE KINASE 3 BETA COMPLEXED WITH 6-BROMOINDIRUBIN-3'-OXIME</PDB_Title>
      <PDB_ID>1UV5</PDB_ID>
      <Resolution>2.8</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1UV5</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Gsk-3-Selective Inhibitors Derived from Tyrian Purple Indurubins</PubMed_Title>
      <Author>Meijer L, et al.</Author>
      <Journal>Chem Biol. 2003 Dec;10(12):1255-66.</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/14700633?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>3-Aryl-4-(arylhydrazono)-1H-pyrazol-5-ones: Highly ligand efficient and potent inhibitors of GSK3</PDB_Title>
      <PDB_ID>3L1S</PDB_ID>
      <Resolution>2.9</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3L1S</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>3-Aryl-4-(arylhydrazono)-1H-pyrazol-5-ones: Highly ligand efficient and potent inhibitors of GSK3beta.</PubMed_Title>
      <Author>Arnost M, et al.</Author>
      <Journal>Bioorg Med Chem Lett. 2010 Mar 1;20(5):1661-4.</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/20138514?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>GSK-3 Beta complexed with Indirubin-3'-monoxime</PDB_Title>
      <PDB_ID>1Q41</PDB_ID>
      <Resolution>2.1</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1Q41</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Structural Characterization of the Gsk-3Beta Active Site Using Selective and Non-selective ATP-Mimetic Inhibitors</PubMed_Title>
      <Author>Bertrand JA, et al.</Author>
      <Journal>J Mol Biol. 2003,333(2):393-407.</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/14529625?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>GSK-3 Beta complexed with AMP-PNP</PDB_Title>
      <PDB_ID>1PYX</PDB_ID>
      <Resolution>2.4</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1PYX</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Structural characterization of the GSK-3beta active site using selective and non-selective ATP-mimetic inhibitors</PubMed_Title>
      <Author>Bertrand JA, et al.</Author>
      <Journal>J Mol Biol. 2003,333(2):393-407.</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/14529625?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal Structure of Akt-1 complexed with substrate peptide and inhibitor</PDB_Title>
      <PDB_ID>3CQU</PDB_ID>
      <Resolution>2.2</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3CQU</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Synthesis and structure based optimization of novel Akt inhibitors</PubMed_Title>
      <Author>Lippa B, et al.</Author>
      <Journal>Bioorg Med Chem Lett. 2008 Jun 1;18(11):3359-63.</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/18456494?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>glycogen synthase Kinase 3beta inhibitor complex</PDB_Title>
      <PDB_ID>3F88</PDB_ID>
      <Resolution>2.6</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3F88</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Design, synthesis and structure-activity relationships of 1,3,4-oxadiazole derivatives as novel inhibitors of glycogen synthase kinase-3beta.</PubMed_Title>
      <Author>Saitoh M, et al.</Author>
      <Journal>Bioorg Med Chem. 2009 Mar 1;17(5):2017-29.</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/19200745?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Glycogen synthase kinase-3 beta in complex with 3-indolyl-4-arylmaleimide inhibitor</PDB_Title>
      <PDB_ID>1R0E</PDB_ID>
      <Resolution>2.25</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1R0E</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>From genetics to therapeutics: the Wnt pathway and osteoporosis</PubMed_Title>
    </PDB>
    <PDB>
      <PDB_Title>Crystal Structure of Akt-1 complexed with substrate peptide and inhibitor</PDB_Title>
      <PDB_ID>3CQW</PDB_ID>
      <Resolution>2.0</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3CQW</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Synthesis and structure based optimization of novel Akt inhibitors</PubMed_Title>
      <Author>Lippa B, et al.</Author>
      <Journal>Bioorg Med Chem Lett. 2008 Jun 1;18(11):3359-63.</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/18456494?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structures of the kinase domain of AKT2 in complex with ATP-competitive inhibitors</PDB_Title>
      <PDB_ID>3E8D</PDB_ID>
      <Resolution>2.7</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3E8D</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Aminofurazans as potent inhibitors of AKT kinase</PubMed_Title>
      <Author>Rouse MB, et al.</Author>
      <Journal>Bioorg Med Chem Lett. 2009 Mar 1;19(5):1508-11.</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/19179070?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>GLYCOGEN SYNTHASE KINASE-3 BETA (GSK3) COMPLEX WITH FRATTIDE PEPTIDE</PDB_Title>
      <PDB_ID>1GNG</PDB_ID>
      <Resolution>2.6</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1GNG</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>The Structure of Phosphorylated Gsk-3Beta Complexed with a Peptide, Frattide, that Inhibits Beta-Catenin Phosphorylation</PubMed_Title>
      <Author>Bax B, et al.</Author>
      <Journal>Structure. 2001 Dec;9(12):1143-52.</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/11738041?dopt=Abstract</PubMed_ID>
    </PDB>
  </PDB_List>
  <Network_List>
    <Network>
      <Pathway_ID>ko05162</Pathway_ID>
      <Pathway_Title>Measles</Pathway_Title>
      <Pathway_Class>Human Diseases</Pathway_Class>
      <Pathway_Subclass>Infectious diseases</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko05169</Pathway_ID>
      <Pathway_Title>Epstein-Barr virus infection</Pathway_Title>
      <Pathway_Class>Human Diseases</Pathway_Class>
      <Pathway_Subclass>Infectious diseases</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko04510</Pathway_ID>
      <Pathway_Title>Focal adhesion</Pathway_Title>
      <Pathway_Class>Cellular Processes</Pathway_Class>
      <Pathway_Subclass>Cellular commiunity</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko04110</Pathway_ID>
      <Pathway_Title>Cell cycle</Pathway_Title>
      <Pathway_Class>Cellular Processes</Pathway_Class>
      <Pathway_Subclass>Cell growth and death</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko05213</Pathway_ID>
      <Pathway_Title>Endometrial cancer</Pathway_Title>
      <Pathway_Class>Human Diseases</Pathway_Class>
      <Pathway_Subclass>Cancers</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko04550</Pathway_ID>
      <Pathway_Title>Signaling pathways regulating pluripotency of stem cells</Pathway_Title>
      <Pathway_Class>Cellular Processes</Pathway_Class>
      <Pathway_Subclass>Cellular commiunity</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko04662</Pathway_ID>
      <Pathway_Title>B cell receptor signaling pathway</Pathway_Title>
      <Pathway_Class>Organismal Systems</Pathway_Class>
      <Pathway_Subclass>Immune system</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko05210</Pathway_ID>
      <Pathway_Title>Colorectal cancer</Pathway_Title>
      <Pathway_Class>Human Diseases</Pathway_Class>
      <Pathway_Subclass>Cancers</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko05215</Pathway_ID>
      <Pathway_Title>Prostate cancer</Pathway_Title>
      <Pathway_Class>Human Diseases</Pathway_Class>
      <Pathway_Subclass>Cancers</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko04722</Pathway_ID>
      <Pathway_Title>Neurotrophin signaling pathway</Pathway_Title>
      <Pathway_Class>Organismal Systems</Pathway_Class>
      <Pathway_Subclass>Nervous system</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko04310</Pathway_ID>
      <Pathway_Title>Wnt signaling pathway</Pathway_Title>
      <Pathway_Class>Environmental Information Processing</Pathway_Class>
      <Pathway_Subclass>Signal transduction</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko05010</Pathway_ID>
      <Pathway_Title>Alzheimer's disease</Pathway_Title>
      <Pathway_Class>Human Diseases</Pathway_Class>
      <Pathway_Subclass>Neurodegenerative diseases</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko05210</Pathway_ID>
      <Pathway_Title>Colorectal cancer</Pathway_Title>
      <Pathway_Class>Human Diseases</Pathway_Class>
      <Pathway_Subclass>Cancers</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko04550</Pathway_ID>
      <Pathway_Title>Signaling pathways regulating pluripotency of stem cells</Pathway_Title>
      <Pathway_Class>Cellular Processes</Pathway_Class>
      <Pathway_Subclass>Cellular commiunity</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko04660</Pathway_ID>
      <Pathway_Title>T cell receptor signaling pathway</Pathway_Title>
      <Pathway_Class>Organismal Systems</Pathway_Class>
      <Pathway_Subclass>Immune system</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko04390</Pathway_ID>
      <Pathway_Title>Hippo signaling pathway</Pathway_Title>
      <Pathway_Class>Environmental Information Processing</Pathway_Class>
      <Pathway_Subclass>Signal transduction</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko04012</Pathway_ID>
      <Pathway_Title>ErbB signaling pathway</Pathway_Title>
      <Pathway_Class>Environmental Information Processing</Pathway_Class>
      <Pathway_Subclass>Signal transduction</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko04728</Pathway_ID>
      <Pathway_Title>Dopaminergic synapse</Pathway_Title>
      <Pathway_Class>Organismal Systems</Pathway_Class>
      <Pathway_Subclass>Nervous system</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko05166</Pathway_ID>
      <Pathway_Title>HTLV-I infection</Pathway_Title>
      <Pathway_Class>Human Diseases</Pathway_Class>
      <Pathway_Subclass>Infectious diseases</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko05164</Pathway_ID>
      <Pathway_Title>Influenza A</Pathway_Title>
      <Pathway_Class>Human Diseases</Pathway_Class>
      <Pathway_Subclass>Infectious diseases</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko04917</Pathway_ID>
      <Pathway_Title>Prolactin signaling pathway</Pathway_Title>
      <Pathway_Class>Organismal Systems</Pathway_Class>
      <Pathway_Subclass>Endocrine system</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko04062</Pathway_ID>
      <Pathway_Title>Chemokine signaling pathway</Pathway_Title>
      <Pathway_Class>Organismal Systems</Pathway_Class>
      <Pathway_Subclass>Immune system</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko04711</Pathway_ID>
      <Pathway_Title>Circadian rhythm - fly</Pathway_Title>
      <Pathway_Class>Organismal Systems</Pathway_Class>
      <Pathway_Subclass>Environmental adaptation</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko04919</Pathway_ID>
      <Pathway_Title>Thyroid hormone signaling pathway</Pathway_Title>
      <Pathway_Class>Organismal Systems</Pathway_Class>
      <Pathway_Subclass>Endocrine system</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko05200</Pathway_ID>
      <Pathway_Title>Pathways in cancer</Pathway_Title>
      <Pathway_Class>Human Diseases</Pathway_Class>
      <Pathway_Subclass>Cancers</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko04340</Pathway_ID>
      <Pathway_Title>Hedgehog signaling pathway</Pathway_Title>
      <Pathway_Class>Environmental Information Processing</Pathway_Class>
      <Pathway_Subclass>Signal transduction</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko04151</Pathway_ID>
      <Pathway_Title>PI3K-Akt signaling pathway</Pathway_Title>
      <Pathway_Class>Environmental Information Processing</Pathway_Class>
      <Pathway_Subclass>Signal transduction</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko04910</Pathway_ID>
      <Pathway_Title>Insulin signaling pathway</Pathway_Title>
      <Pathway_Class>Organismal Systems</Pathway_Class>
      <Pathway_Subclass>Endocrine system</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko05217</Pathway_ID>
      <Pathway_Title>Basal cell carcinoma</Pathway_Title>
      <Pathway_Class>Human Diseases</Pathway_Class>
      <Pathway_Subclass>Cancers</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko04360</Pathway_ID>
      <Pathway_Title>Axon guidance</Pathway_Title>
      <Pathway_Class>Organismal Systems</Pathway_Class>
      <Pathway_Subclass>Development</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko04932</Pathway_ID>
      <Pathway_Title>Non-alcoholic fatty liver disease (NAFLD)</Pathway_Title>
      <Pathway_Class>Human Diseases</Pathway_Class>
      <Pathway_Subclass>Endocrine and metabolic diseases</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko04916</Pathway_ID>
      <Pathway_Title>Melanogenesis</Pathway_Title>
      <Pathway_Class>Organismal Systems</Pathway_Class>
      <Pathway_Subclass>Endocrine system</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko05160</Pathway_ID>
      <Pathway_Title>Hepatitis C</Pathway_Title>
      <Pathway_Class>Human Diseases</Pathway_Class>
      <Pathway_Subclass>Infectious diseases</Pathway_Subclass>
    </Network>
  </Network_List>
  <Fold>
    <SCOP_Class>Alpha and beta proteins (a+b)</SCOP_Class>
    <SCOP_URL>http://scop.mrc-lmb.cam.ac.uk/scop/data/scop.b.e.daa.b.b.bb.html</SCOP_URL>
    <CATH_Class>Class 3: Mixed Alpha-Beta</CATH_Class>
    <CATH_URL>http://www.cathdb.info/pdb/1gng</CATH_URL>
  </Fold>
  <AllostericSite_List>
    <AllostericSite>
      <Site_Reference>Palomo V, et al. J Med Chem. 2011,54(24):8461-8470.</Site_Reference>
      <PubMed_ID>22050263</PubMed_ID>
    </AllostericSite>
  </AllostericSite_List>
  <Enzyme_Nomenclature_List>
    <Enzyme_Nomenclature>
      <Enzyme_DB_ID>2.7.11.26</Enzyme_DB_ID>
      <Enzyme_DB_URL>http://www.chem.qmul.ac.uk/iubmb/enzyme/EC2/7/11/26.html</Enzyme_DB_URL>
    </Enzyme_Nomenclature>
  </Enzyme_Nomenclature_List>
  <Modulator_List>
    <Modulator>
      <ASD_ID>ASD04930001</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
  </Modulator_List>
  <Create_Date>2012-06-20</Create_Date>
</Organism_Record>